Moderna has reported preliminary clinical ... "We believe that a bivalent booster vaccine, if authorised, would create a new tool as we continue to respond to emerging variants," added Bancel.

Pfizer (NYSE:PFE) and other pandemic-era favorites will be back in the investors’ crosshairs following the resignation of Dr.

The CDC also recommends that people who had an allergic reaction to the first MMR vaccine hold off on getting the second dose ...

Nearly 400 cases of measles have been reported in the U.S. so far this year, and 95% of the cases have been in people who ...

Starting from April 8, people aged 65 and older, indigenous people aged 55 to 64, children younger than six months old and ...

The UK has become the first country in the world to authorise an updated COVID-19 booster vaccine directed at the Omicron variant, giving a green light to Moderna's mRNA-1273.214 shot.

Moderna developed its vaccine in partnership with the National ... making this approach potentially less useful if booster shots need to be given. Viral-vectored vaccines, developed by ...

GEO-CM04S1 BARDA/Project NextGen Phase 2b trial preparations ongoing with manufacturing of clinical trial materials underway ...

As measles cases continue to spread across the United States, experts reveal who may need another vaccine dose and who is ...

Moderna is recognized as a pioneer in messenger ... Shifting sentiment about the need for annual booster vaccination, competition from alternative therapeutics, and the withdrawal of emergency ...

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet ...